Whiley David M, Trembizki Ella, Buckley Cameron, Freeman Kevin, Baird Robert W, Beaman Miles, Chen Marcus, Donovan Basil, Kundu Ratan L, Fairley Christopher K, Guy Rebecca, Hogan Tiffany, Kaldor John M, Karimi Mahdad, Limnios Athena, Regan David G, Ryder Nathan, Su Jiunn-Yih, Ward James, Lahra Monica M
Emerg Infect Dis. 2017 Sep;23(9):1478-1485. doi: 10.3201/eid2309.170427.
Neisseria gonorrhoeae antimicrobial resistance (AMR) is a globally recognized health threat; new strategies are needed to enhance AMR surveillance. The Northern Territory of Australia is unique in that 2 different first-line therapies, based primarily on geographic location, are used for gonorrhea treatment. We tested 1,629 N. gonorrhoeae nucleic acid amplification test-positive clinical samples, collected from regions where ceftriaxone plus azithromycin or amoxicillin plus azithromycin are recommended first-line treatments, by using 8 N. gonorrhoeae AMR PCR assays. We compared results with those from routine culture-based surveillance data. PCR data confirmed an absence of ceftriaxone resistance and a low level of azithromycin resistance (0.2%), and that penicillin resistance was <5% in amoxicillin plus azithromycin regions. Rates of ciprofloxacin resistance and penicillinase-producing N. gonorrhoeae were lower when molecular methods were used. Molecular methods to detect N. gonorrhoeae AMR can increase the evidence base for treatment guidelines, particularly in settings where culture-based surveillance is limited.
淋病奈瑟菌抗菌药物耐药性(AMR)是一种全球公认的健康威胁;需要新的策略来加强AMR监测。澳大利亚北领地的独特之处在于,主要基于地理位置,两种不同的一线治疗方法用于淋病治疗。我们使用8种淋病奈瑟菌AMR PCR检测方法,对1629份淋病奈瑟菌核酸扩增检测呈阳性的临床样本进行了检测,这些样本采集自推荐头孢曲松加阿奇霉素或阿莫西林加阿奇霉素作为一线治疗方法的地区。我们将结果与基于常规培养的监测数据进行了比较。PCR数据证实不存在头孢曲松耐药性,阿奇霉素耐药性水平较低(0.2%),在阿莫西林加阿奇霉素治疗地区青霉素耐药性<5%。当使用分子方法时,环丙沙星耐药率和产青霉素酶淋病奈瑟菌的发生率较低。检测淋病奈瑟菌AMR的分子方法可以增加治疗指南的证据基础,特别是在基于培养的监测有限的情况下。